A scientific review highlights how mitochondrial metabolic shifts enable tumor immune evasion and resistance to cancer immunotherapy. The analysis focuses on mitochondrial reprogramming as a mechanistic bridge between cancer cell bioenergetics and compromised immune activation, outlining candidate intervention points to overcome failure to respond. The review summarizes evidence for how changes in mitochondrial function can alter antigen processing, immune cell infiltration, and immunotherapy sensitivity, while emphasizing that translation has been constrained by the complexity of metabolic phenotypes. The paper consolidates current preclinical strategies aimed at restoring immunogenicity via metabolic targeting.
Get the Daily Brief